These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 19008117)

  • 1. Sphingolipids: players in the pathology of metabolic disease.
    Cowart LA
    Trends Endocrinol Metab; 2009 Jan; 20(1):34-42. PubMed ID: 19008117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sphingolipids, insulin resistance, and metabolic disease: new insights from in vivo manipulation of sphingolipid metabolism.
    Holland WL; Summers SA
    Endocr Rev; 2008 Jun; 29(4):381-402. PubMed ID: 18451260
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sphingolipids in metabolic disease: The good, the bad, and the unknown.
    Green CD; Maceyka M; Cowart LA; Spiegel S
    Cell Metab; 2021 Jul; 33(7):1293-1306. PubMed ID: 34233172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipid microdomains and insulin resistance: is there a connection?
    Ikonen E; Vainio S
    Sci STKE; 2005 Jan; 2005(268):pe3. PubMed ID: 15671480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sphingolipids and insulin resistance: the five Ws.
    Summers SA
    Curr Opin Lipidol; 2010 Apr; 21(2):128-35. PubMed ID: 20216312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance.
    Holland WL; Brozinick JT; Wang LP; Hawkins ED; Sargent KM; Liu Y; Narra K; Hoehn KL; Knotts TA; Siesky A; Nelson DH; Karathanasis SK; Fontenot GK; Birnbaum MJ; Summers SA
    Cell Metab; 2007 Mar; 5(3):167-79. PubMed ID: 17339025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A ceramide-centric view of insulin resistance.
    Chavez JA; Summers SA
    Cell Metab; 2012 May; 15(5):585-94. PubMed ID: 22560211
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sphingolipid signalling in the cardiovascular system: good, bad or both?
    Alewijnse AE; Peters SL
    Eur J Pharmacol; 2008 May; 585(2-3):292-302. PubMed ID: 18420192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sphingolipids and Lipoproteins in Health and Metabolic Disorders.
    Iqbal J; Walsh MT; Hammad SM; Hussain MM
    Trends Endocrinol Metab; 2017 Jul; 28(7):506-518. PubMed ID: 28462811
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sphingolipids: major regulators of lipid metabolism.
    Worgall TS
    Curr Opin Clin Nutr Metab Care; 2007 Mar; 10(2):149-55. PubMed ID: 17285002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sphingolipids in infectious diseases.
    Hanada K
    Jpn J Infect Dis; 2005 Jun; 58(3):131-48. PubMed ID: 15973004
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Translational aspects of sphingolipid metabolism.
    Zeidan YH; Hannun YA
    Trends Mol Med; 2007 Aug; 13(8):327-36. PubMed ID: 17588815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sphingolipids in obesity, type 2 diabetes, and metabolic disease.
    Russo SB; Ross JS; Cowart LA
    Handb Exp Pharmacol; 2013; (216):373-401. PubMed ID: 23563667
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular facets of sphingolipids: mediators of diseases.
    Ozbayraktar FB; Ulgen KO
    Biotechnol J; 2009 Jul; 4(7):1028-41. PubMed ID: 19579220
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sphingolipid metabolism and analysis in metabolic disease.
    Brice SE; Cowart LA
    Adv Exp Med Biol; 2011; 721():1-17. PubMed ID: 21910079
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiological and pathophysiological roles of adiponectin and adiponectin receptors in the integrated regulation of metabolic and cardiovascular diseases.
    Yamauchi T; Kadowaki T
    Int J Obes (Lond); 2008 Dec; 32 Suppl 7():S13-8. PubMed ID: 19136982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct and macrophage-mediated actions of fatty acids causing insulin resistance in muscle cells.
    Bilan PJ; Samokhvalov V; Koshkina A; Schertzer JD; Samaan MC; Klip A
    Arch Physiol Biochem; 2009 Oct; 115(4):176-90. PubMed ID: 19671019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of intramuscular triglycerides: contribution to metabolic abnormalities.
    Dubé J; Goodpaster BH
    Curr Opin Clin Nutr Metab Care; 2006 Sep; 9(5):553-9. PubMed ID: 16912550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of obesity and related pathologies: role of apolipoprotein E in the development of obesity.
    Kypreos KE; Karagiannides I; Fotiadou EH; Karavia EA; Brinkmeier MS; Giakoumi SM; Tsompanidi EM
    FEBS J; 2009 Oct; 276(20):5720-8. PubMed ID: 19754875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adipose tissue dysfunction in obesity.
    Blüher M
    Exp Clin Endocrinol Diabetes; 2009 Jun; 117(6):241-50. PubMed ID: 19358089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.